DO Dow Jones Newswires VERAXA Biotech Initiates Cell Line Development With ATUM to Advance Its Lead BiTAC-TCE Program 7/2/2026, 07:00 PM GMT+8 Dow Jones Newswires 35 355690 VR VRXA Sources Dow Jones Newswires Markets Stocks Active symbols KRX:355690, NASDAQ:VRXA Language English VERAXA Biotech Initiates Cell Line Development With ATUM to Advance Its Lead BiTAC-TCE Program Market News FinanceWire VERAXA Biotech (NASDAQ: VRXA) Initiates Cell Line Development for Lead BiTAC Cancer Therapy Program Reuters Veraxa Biotech Initiates Cell Line Development With ATUM GlobeNewswire VERAXA Biotech Initiates Cell Line Development with ATUM to Advance its Lead BiTAC®-TCE Program FinanceWire Why VERAXA Biotech (NASDAQ: VRXA) Shareholders Should Pay Serious Attention to Antibody Therapeutics Sector Deals
